Tanvex BioPharma, Inc. held road show presentation on July 20, 2017

Taipei, Taiwan, July 20, 2017

Tanvex BioPharma Inc. ("Tanvex", stock code 6541) held road show presentation on July 20, 2017 and will go for primary listing on the Taiwan Stock Exchange on Aug. 17, 2017.

Tanvex is developing biosimilar drugs to treat neutropenia, breast cancer, metastatic colon cancer, lung cancer, rheumatoid arthritis and other conditions – conditions that affect millions of people. We commenced Phase III clinical trials in 2016 which are estimated to be completed by the end of 2017 to support our planned BLA filing for TX01 (the filgrastim (Neupogen®) biosimilar candidate) in 2018 in the U.S. We also successfully completed our Phase I trials for TX05 (the trastuzumab (Herceptin®) biosimilar candidate) in second quarter in 2016. It is estimated that we could receive FDA approval to enter into the Phase III clinical trial by the end of 2017. Our TX16 (the bevacizumab (Avastin®) biosimilar candidate) had received FDA approval in January 2017 to enter into Phase I clinical trial. It is estimated that we could complete the trial by the end of 2017. Our TX17 (the adalimumab (Humira®) biosimilar candidate) is still being develop in our laboratory.

In 1984, the U.S. federal government established the Hatch-Waxman Act. This law was created to spur the development and utilization of generic pharmaceutical products and ultimately revolutionized the generic drug industry. In 2015, annual sales of generics in the U.S. are approximately $75 billion, roughly 89% of prescriptions in the U.S. are filled with generics. It has resulted in trillion dollars of savings for the U.S. healthcare system in the last ten year (2006-2015) .

Like it did with generics in the early 80's, the United States recognized the need to create a clear and efficient pathway for biosimilar regulation and market access. In 2010, the U.S. established the Biologics Price Competition and Innovation Act ("BPCIA"). The BPCIA should provide for the next wave of tremendous cost savings for the U.S. healthcare system, while creating a boon for the biosimilar industry. Biosimilars are expected to exceed $26 billion worldwide by 2020 according to the report of Biosimilars Market Overview of Allied Market Research.

###